LGC Clinical Diagnostics’ Post

Get our AMP 2024 posters while the're hot! 🧬 "The Next Generation of Reference Materials for Analytical Validation of Liquid Biopsy Assays" brings lots of data together from the testing of the new ctDNA v4, including the first-hand proof of reduced background mutation rate! 💊 "Multi-site Evaluation of a Reference Material for Analysis of Genetic Variants of DPYD" showcases the compatibility with various DPYD testing methodologies. 🔬 "Improvement of Formalin-Fixed Paraffin-Embedded Reference Materials for Molecular Analyses" describes a new approach to making FFPE reference materials, includign better reproducibility and full-process compatibility starting from slides.

Missed our Genetic Engineering & Biotechnology News webinar last week? We've got you! The recording is now available. Catch Ettai Markovits and Arutha Kulasinghe discussing AI's role in discovering biomarkers for immunotherapy through spatial analysis of mIF data. Visit the link to watch now! https://lnkd.in/gMktYiir #immunotherapy #spatialbiomarkers #CDx #mIF #digitalpathology #biomarkers #precisionmedicine

It is critical that DNA-based genomic profiling (CGP) tests are optimally designed to identify fusions, which are important driver events that can significantly influence treatment decisions & patient outcomes. #NewResearch demonstrates that robust detection of fusions is possible using carefully designed DNA-based sequencing methodologies and, in an analysis of nonsquamous NSCLC, that fusions detected using high-quality DNA CGP assays are associated with clinical benefit from matched targeted agents. Read more in our latest research spotlight: https://bit.ly/49N1x3R

When it comes to in vitro diagnostics, selecting the right approach is crucial. 🔬 🔵 #Immunoassays: Ideal for quick, cost-effective testing of proteins or antigens. 🔵 #MolecularAssays: Best for high-sensitivity genetic testing and early pathogen detection. Explore key considerations like sample type, sensitivity, and speed to help guide your choice: https://bit.ly/40hqGA9

Network Medicines™ are a new class of therapeutic with the potential to transform the treatment of complex diseases that are driven by multicellular networks, such as #cancer and #fibrosis. They are designed to have both a direct effect by targeting diseased cells themselves and a network effect by reprogramming diseased cells to release therapeutic signals that coordinate other key cells in the network to restore health. Read more about Network Medicines as well as some of the other new science being pioneered by fellow #FlagshipFounded companies below. 

We often talk about #DRAGEN secondary analysis in the context of germline analysis, but DRAGEN can do so much more! It's great to read this latest blog which delves into the new DRAGEN Heme Recipe, built on the #Somatic pipeline to enable accurate and comprehensive calling for key variants commonly assessed in hematological malignancies, such as AML/MDS. Who wouldn't want to be able to accurately detect SNVs and chromosomal anomalies, including #DUX4 and #FLT3ITD variants, and then automatically ingest the results into Illumina Connected Insights for interpretation? 😉 #WGSheme #bioinformatics #AML #MDS #hematology #sequencing

Read our latest blog on the applications of WGS sequencing in hematologic malignancies, and the new DRAGEN workflow to support it. WGS enables comprehensive genomic profiling for hematological malignancies, detecting structural variants and chromosomal changes that can be missed by traditional methods like cytogenetics and FISH. In AML/MDS, a recent study showed that WGS revealed additional findings in ~25% of cases and altered risk stratification in ~17% compared with current standard methods.  #DRAGEN now provides accurate and comprehensive calling for key variants commonly assessed in hematological malignancies. Single nucleotide variants and chromosomal anomalies can be assessed accurately with the DRAGEN Somatic WGS Heme workflow, including DUX4 variants, and the results automatically ingested and interpreted with Connected Insights.  https://lnkd.in/g_qg7zN6 #wgsheme #bioinformatics #heme #hematalogy #aml #mds #sequencing

What makes Candida auris pan-drug resistant? Integrative insights from genomic, transcriptomic, and phenomic analysis of clinical strains resistant to all four major classes of antifungal drugs https://lnkd.in/epkMFEJb

The tools available to scientists and clinicians in the field of genetics are evolving rapidly. Our latest blog explores the power of low-pass WGS in pharmacogenomics, sharing a collaboration between GSK and Gencove that investigated the performance of low-pass WGS compared to genotyping arrays for PGx. Additionally, we discuss another recent experiment in which we designed an assay combining lpWGS with a panel of hybrid capture probes that specifically enrich PGx genes (including CYP2D6), resulting in high sequencing coverage at the enriched genes. Read on here: https://lnkd.in/gumzFHDF

Ahead of the curve…